Cogprints

Atrial Fibrillation and Hyperthyroidism

Jayaprasad, N and Francis, Johnson (2005) Atrial Fibrillation and Hyperthyroidism. [Journal (Paginated)]

Full text available as:

[img]HTML
57Kb
[img]
Preview
PDF
141Kb

Abstract

Atrial fibrillation occurs in 10 – 15% of patients with hyperthyroidism. Low serum thyrotropin concentration is an independent risk factor for atrial fibrillation. Thyroid hormone contributes to arrythmogenic activity by altering the electrophysiological characteristics of atrial myocytes by shortening the action potential duration, enhancing automaticity and triggered activity in the pulmonary vein cardio myocytes. Hyperthyroidism results in excess mortality from increased incidence of circulatory diseases and dysrhythmias. Incidence of cerebral embolism is more in hyperthyroid patients with atrial fibrillation, especially in the elderly and anti-coagulation is indicated in them. Treatment of hyperthyroidism results in conversion to sinus rhythm in up to two-third of patients. Beta-blockers reduce left ventricular hypertrophy and atrial and ventricular arrhythmias in patients with hyperthyroidism. Treatment of sub clinical hyperthyroidism is controversial. Optimizing dose of thyroxine treatment in those with replacement therapy and beta-blockers is useful in exogenous subclinical hyperthyroidism.

Item Type:Journal (Paginated)
Keywords:Atrial fibrillation; hyperthyroidism; embolism
Subjects:JOURNALS > Indian Pacing and Electrophysiology Journal
ID Code:4597
Deposited By:Indian Pacing and Electrophysiology, Journal
Deposited On:12 Nov 2005
Last Modified:11 Mar 2011 08:56

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

1. Sawin CT, Geller A, Wolf P, Belanger A, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D’agostino RB . Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med.1994; 331:1249–1252.

2. Forfar JC, Miller HC, Toft AD. Occult thyrotoxicosis: a reversible cause of “idiopathic” atrial fibrillation. Am J Cardiol. 1979;44:9-12.

3. Staffurth JS, Gibberd JS, Tang FS. Arterial embolism in thyrotoxicosis with atrial fibrillation. Br Med J.1977; 2:688–690.

4. Lazar MA . Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev .1993;24:184–193.

5. Rohrer D, Dillmann WH. Thyroid hormone markedly increases the mRNA coding for sarcoplasmic reticulum Ca2+-ATPase in the rat heart. J Biol Chem.1988; 263:6941–6944.

6. Arai M, Otsu K, MacLennan DH, Alpert NR, Periasamy M Effect of thyroid hormone on the expression of mRNA encoding sarcoplasmic reticulum proteins. Circ Res.1991; 69:266–276.

7. Dudley SC, Baumgarten CM. Bursting of cardiac sodium channels after acute exposure to 3,5,3_-triiodo-L-thyronine. Circ Res. 1993; 73:301–313.

8. Shimoni Y, Severson DL.Thyroid status and potassium currents in rat ventricular myocytes. Am J Physiol.1995; 268:H576–H583.

9. Klein I, Ojamaa K .Thyroid hormone and the cardiovascular system. N Engl J Med .2001;344:501–509.

10. Ojamaa K, Klemperer JD, Klein I . Acute effects of thyroid hormone on vascular smooth muscle. Thyroid.1996; 6:505–512.

11. Polikar R, Feld GK, Dittrich HC, Smith J, Nicod P .Effect of thyroid replacement therapy on the frequency of benign atrial and ventricular arrhythmias. J Am Coll Cardiol.1989; 14:999–1002.

12. Agner T, Almdal T, Thorsteinsson B, Agner E . A reevaluation of atrial fibrillation in thyrotoxicosis. Dan Med Bull .1984;31:157–159.

13. Iwasaki T, Naka M, Hiramatsu K, Yamada T, Niwa A, Aizawa T, Murakami M, Ishihara M, Miyahara Y . Echocardiographic studies on the relationship between atrial fibrillation and atrial enlargement in patients with hyperthyroidism of Graves’ disease. Cardiology.1989; 76:10–17.

14. Krahn AD, Klein GJ, Kerr CR, et al. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? Arch Intern Med.1996;156:2221-4.

15. Lars Frost, Peter Vestergaard, Leif Mosekilde . Hyperthyroidism and Risk of Atrial Fibrillation or Flutter -A Population-Based Study. Arch Intern Med. 2004;164:1675-1678.

16. Franklyn J, Maisonneuve P, Sheppard M, Betteridge J, Boyle P . Mortality after treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998; 338:712–718

17. Goldman MB, Maloof F, Monson RR, Aschengrau A, Cooper DS, Ridgway EC Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women. Am J Epidemiol.1988; 127:969–980.

18. Bagchi N, Brown T, Parish R . Thyroid dysfunction in adults over age 55 years. A study in an urban US community. Arch Intern Med .1990; 150:785–787.

19. Parle J, Franklyn J, Cross K, Jones C . Prevalence and follow-up of abnormal thyrotropin concentrations in the elderly in the United Kingdom. Clin Endocrinol .1991;34:77–83.

20. Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J .2001;142:838–842.

21. Biondi B, Fazio S, Carella C, Amato G, Cittadini A, Lupoli G, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levo-thyroxine. J Clin Endocrinol Metab. 1993;77:334-8.

22. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA Prediction of all cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet.2001; 358:861–865.

23. Watanabe H, Ma M, Washizuka T, Komura S, Yoshida T, Hosaka Y, Hatada K, Chinushi M, Yamamoto T, Watanabe K, Aizawa Y. Thyroid hormone regulates mRNA expression and currents of ion channels in rat atrium. Biochem Biophys Res Commun. 2003;308(3):439-44.

24. Hu Y, Jones SV, Dillmann WH.Effects of Hyperthyroidism on Delayed Rectifier Potassium Currents in Left and Right Murine Atrium. Am J Physiol Heart Circ Physiol. 2005 ;May 13. [Epub ahead of print]

25. Yao-Chang Chen, Shih-Ann Chen, Yi-Jen Chen, Mau-Song Chang, Paul Chan,Cheng-I. Lin. Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes J Am Coll Cardiol, 2002; 39:366-372.

26. Aras D, Maden O, Ozdemir O, Aras S, Topaloglu S, Yetkin E, Demir AD, Soylu MO, Erdogan MF, Kisacik HL, Korkmaz S. Simple electrocardiographic markers for the prediction of paroxysmal atrial fibrillation in hyperthyroidism . Int J Cardiol. 2005; 99(1):59-64.

27. Maciel B, Gallo L, Marin Neto J, Maciel L, Martins L . Autonomic control of heart rate during dynamic exercise in human hyperthyroidism. Clin Sci.1988; 75:209–215.

28. Dratman M, Goldman M, Crutchfield F, Gordon J . Nervous system role of iodocompounds in blood pressure regulation. Life Sci .1982;30:611–622.

29. Osman F, Daykin J, Sheppard M, Franklyn J, Gammage M. Cardiac rhythm abnormalities in thyrotoxicosis—the explanation for excess vascular mortality. J Endocrinol. 2000; 164:P321.

30. Petersen P, Hansen JM. Stroke in thyrotoxicosis with atrial fibrillation. Stroke 1988;19:15-8.

31. Presti C, Hart R. Thyrotoxicosis, atrial fibrillation, and embolism, revisited. Am Heart J.1989; 117:976–977.

32. Gilligan DM, Ellenbogen KA, Epstein AE. The management of atrial fibrillation. Am J Med 1996;101:413-21.

33. Miller V, Pearce L, Feinberg W, Rothrock J, Anderson D, Hart R . Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Neurology.1996; 46:238–240.

34. Mintz G, Pizzarello R, Klein I. Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. J Clin Endocrinol Metab .1991;73:146-50.

35. Klein I, Becker DV, Levey GS. Treatment of hyperthyroid disease. Ann Intern Med 1994;121:281-8.

36. Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 1982;72: 903-6.

37. Fierro N, Gonnella C, Pietropaolo L, Morelli A, Di Cola G, D'Ermo G, Galassi G Jr, Galassi G. Atrial fibrillation and hyperthyroidism: results after thyroidectomy. G Chir. 2002;23(11-12):431-3.

38. Koutras D . Subclinical hyperthyroidism. Thyroid .1999; 9:311–315.

39. Toft AD. Clinical practice. Subclinical hyperthyroidism. N Engl J Med . 2001; 345:512–516.

40. Sgarbi JA, Villaca FG, Garbeline B, Villar HE, Romaldini JH. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab. 2003 Apr;88(4):1672-7.

41. Biondi B, Fazio S, Carella C, Sabatini D, Amato G, Cittadini A, Bellastella A, Lombardi G, Sacca L. Control of adrenergic overactivity by beta blockade improves quality of life in patients on long-term suppressive therapy with levothyroxine. J Clin Endocrinol Metab.1994; 78:1028–1033.

42. Mercuro G, Panzuto MG, Bina A, Leo M, Cabula R, Petrini L, Pigliaru F, Mariotti S . Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab .2000;85:159–164.

Metadata

Repository Staff Only: item control page